A detailed history of D. E. Shaw & Co., Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 163,348 shares of BMRN stock, worth $10.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
163,348
Holding current value
$10.7 Million
% of portfolio
0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$69.02 - $93.84 $7.25 Million - $9.86 Million
-105,026 Reduced 39.13%
163,348 $11.5 Million
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $11.5 Million - $14.2 Million
-153,924 Reduced 36.45%
268,374 $22.1 Million
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $19.3 Million - $22.8 Million
229,846 Added 119.43%
422,298 $36.9 Million
Q4 2023

Feb 14, 2024

SELL
$76.22 - $98.51 $25.3 Million - $32.7 Million
-331,687 Reduced 63.28%
192,452 $18.6 Million
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $32.8 Million - $36.4 Million
-385,678 Reduced 42.39%
524,139 $46.4 Million
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $19.2 Million - $22.2 Million
-221,222 Reduced 19.56%
909,817 $78.9 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $24.4 Million - $32.6 Million
-278,085 Reduced 19.73%
1,131,039 $110 Million
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $31.6 Million - $42.4 Million
389,867 Added 38.25%
1,409,124 $146 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $2.4 Million - $2.84 Million
-29,260 Reduced 2.79%
1,019,257 $86.4 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $25.8 Million - $31.3 Million
360,411 Added 52.38%
1,048,517 $86.9 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $17.4 Million - $21.7 Million
-233,616 Reduced 25.35%
688,106 $53.1 Million
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $10.5 Million - $13.4 Million
146,110 Added 18.84%
921,722 $81.4 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $19 Million - $21.8 Million
254,731 Added 48.9%
775,612 $59.9 Million
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $4.35 Million - $4.88 Million
-57,605 Reduced 9.96%
520,881 $43.5 Million
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $752,904 - $913,701
-10,075 Reduced 1.71%
578,486 $43.7 Million
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $38.3 Million - $47.6 Million
527,231 Added 859.66%
588,561 $51.6 Million
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $4.08 Million - $7.44 Million
56,804 Added 1255.06%
61,330 $4.67 Million
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $7.39 Million - $11.5 Million
-92,959 Reduced 95.36%
4,526 $558,000
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $12.7 Million - $17.3 Million
-178,603 Reduced 64.69%
97,485 $8.24 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $8.55 Million - $11.5 Million
132,987 Added 92.93%
276,088 $23.3 Million
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $3.82 Million - $4.82 Million
56,666 Added 65.56%
143,101 $9.65 Million
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $2.08 Million - $2.43 Million
-25,835 Reduced 23.01%
86,435 $7.4 Million
Q1 2019

May 15, 2019

SELL
$84.2 - $98.62 $10.4 Million - $12.2 Million
-123,499 Reduced 52.38%
112,270 $9.97 Million
Q4 2018

Feb 14, 2019

BUY
$80.14 - $106.07 $11 Million - $14.6 Million
137,558 Added 140.06%
235,769 $20.1 Million
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $7.66 Million - $8.62 Million
81,567 Added 490.07%
98,211 $9.52 Million
Q2 2018

Aug 14, 2018

SELL
$76.01 - $99.03 $5.25 Million - $6.84 Million
-69,066 Reduced 80.58%
16,644 $1.57 Million
Q1 2018

May 15, 2018

SELL
$77.67 - $92.63 $6.06 Million - $7.22 Million
-77,964 Reduced 47.63%
85,710 $6.95 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $5.81 Million - $6.84 Million
71,882 Added 78.31%
163,674 $14.6 Million
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $7.4 Million - $8.72 Million
91,792
91,792 $8.54 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.